Scholarlink

<p>Elevated levels of blood-based biomarkers such as neurofilament light chain (NfL) and neuron-specific enolase (NSE) are associated with poor neurological outcome after out-of-hospital cardiac arrest (OHCA). This study investigates the relationship between regional grey matter volume reduction and levels of glial fibrillary acidic protein (GFAP), NfL, NSE, and total-tau (t-tau) protein. This substudy of the Xe-Hypotheca trial included 110 patients randomized to receive either inhaled xenon with target temperature management (TTM) at 33&#xa0;°C for 24&#xa0;h (<i>n</i> = 55) or TTM alone (<i>n</i> = 55). Voxel-based morphometry was used to assess grey matter volume changes in MRI scans acquired 36–52&#xa0;h and 10&#xa0;days after OHCA in 45 survivors. Blood biomarkers were measured upon intensive care unit arrival and at 24, 48 and 72&#xa0;h post-OHCA. NfL levels positively correlated with grey matter volume reduction in the thalamus and cingulate cortex at 24&#xa0;h post-OHCA. T-tau showed more extensive pattern of significant correlations, increasing in both magnitude and spatial extent from baseline to 48&#xa0;h post-OHCA. No significant biomarker–volume associations were observed for GFAP or NSE, and no treatment group differences were detected. Elevated NfL and t-tau levels were associated with region-specific grey matter volume reduction within the first 10&#xa0;days after OHCA. Among the four biomarkers studied, t-tau demonstrated the strongest and most widespread associations, suggesting its potential as a marker for early ischemic grey matter volume reduction after OHCA. ClinicalTrials.gov NCT00879892, 13/04/2009.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Grey matter volume reduction and its association with brain-enriched blood biomarkers in out-of-hospital cardiac arrest survivors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Carita C. Hollmén,
  • Victor Vorobyev,
  • Riitta Parkkola,
  • Jussi P. Posti,
  • Jani Saunavaara,
  • Ruut Laitio,
  • Olli Arola,
  • Marja Hynninen,
  • Minna Bäcklund,
  • Kaj Blennow,
  • Henrik Zetterberg,
  • Juha Martola,
  • Emmi Ylikoski,
  • Risto O. Roine,
  • Marjaana Tiainen,
  • Harry Scheinin,
  • Mervyn Maze,
  • Tero Vahlberg,
  • Timo T. Laitio,
  • Sami Virtanen,
  • Juhani Airaksinen,
  • Antti Saraste,
  • Mikko Pietilä,
  • Juha Grönlund,
  • Outi Inkinen,
  • Veli-Pekka Harjola,
  • Kirsi Korpi,
  • Marjut Varpula,
  • Jussi Niiranen,
  • Eija Nukarinen,
  • Johanna Wennervirta,
  • Klaus T. Olkkola,
  • Päivi Silvasti,
  • Heli Silvennoinen,
  • Leena Valanne

摘要

Elevated levels of blood-based biomarkers such as neurofilament light chain (NfL) and neuron-specific enolase (NSE) are associated with poor neurological outcome after out-of-hospital cardiac arrest (OHCA). This study investigates the relationship between regional grey matter volume reduction and levels of glial fibrillary acidic protein (GFAP), NfL, NSE, and total-tau (t-tau) protein. This substudy of the Xe-Hypotheca trial included 110 patients randomized to receive either inhaled xenon with target temperature management (TTM) at 33 °C for 24 h (n = 55) or TTM alone (n = 55). Voxel-based morphometry was used to assess grey matter volume changes in MRI scans acquired 36–52 h and 10 days after OHCA in 45 survivors. Blood biomarkers were measured upon intensive care unit arrival and at 24, 48 and 72 h post-OHCA. NfL levels positively correlated with grey matter volume reduction in the thalamus and cingulate cortex at 24 h post-OHCA. T-tau showed more extensive pattern of significant correlations, increasing in both magnitude and spatial extent from baseline to 48 h post-OHCA. No significant biomarker–volume associations were observed for GFAP or NSE, and no treatment group differences were detected. Elevated NfL and t-tau levels were associated with region-specific grey matter volume reduction within the first 10 days after OHCA. Among the four biomarkers studied, t-tau demonstrated the strongest and most widespread associations, suggesting its potential as a marker for early ischemic grey matter volume reduction after OHCA. ClinicalTrials.gov NCT00879892, 13/04/2009.